The human immune system, when activated excessively and unlimitedly, can have pathological consequences. Extensive studies with innovative and rigorous methodologies have broadened our knowledge in this regard. Autoimmune and inflammatory diseases are split into two groups, but considering their similarities, can be considered as only one. Both autoimmune and inflammatory responses coexist, with the balance between the two being critical in shaping the clinical presentation of these diseases. Therapeutic cross-manipulations of these processes can be achieved by both the immunoregulatory and anti-inflammatory effects of various innovative compounds, including small-molecule drugs, vaccines and biologics. Immunopharmacology and inflammopharmacology are currently devoted to the discovery, development and implementation of preclinical and clinical molecules that can target the immune system or inflammation, respectively. What is even more highly anticipated, however, is the identification - at the level of individual cells - of molecular patterns and trajectories of pharmaceutical particles with bridged immunoregulatory and anti-inflammatory effects in the affected body, i.e. disturbed by conditions associated with immune-mediated inflammatory skin pathologies.
The goal of this Research Topic is to feature cutting-edge, high-resolution research describing the signature of pharmaceutical molecules in a single cell, related to the regulation of immune-inflammatory axis distortion of human diseases. Reports on strategies that could change the current standards for future patient management and reports on the assessment of efficacy, safety and quality of future health products are missing. Thus, perspectives on the most innovative immuno-inflammatory factors and pharmacological regulators are welcome. Experimental reports on and reviews of systemic and holistic approaches allowing clinicians to institute targeted and personalized medicine, leading to maximization of efficacy and minimization of toxicity, are sought. Such studies will allow us to overcome the biggest challenge we face in achieving more effective and safer, as well as long-term and stable remission in patients suffering from autoimmune inflammatory skin diseases. We believe that this Research Topic will show that expanding this area of research will be very valuable in better understanding of autoimmune inflammatory skin diseases and facilitate the progress of therapeutic procedures for them.
In this Research Topic, we are looking to publish studies that will fuel basic, translational and clinical research on immune-mediated inflammatory skin conditions. This collection should be a forum that allows communication between scientists, which will ultimately propel the translation of fundamental knowledge into early and improved pharmacological treatments for immune-mediated inflammatory skin conditions.
We welcome submissions of Original Research and Review articles addressing, but not limited to, the following aspects of pharmaceutical molecules with bridged immunoregulatory and anti-inflammatory action, in relation to autoimmune inflammatory skin diseases:
• Innovative therapy development strategies related to the identification of molecular patterns that better predict response to a given treatment; mechanisms of response and non-response to treatment using single-cell technologies and advanced bioinformatics.
• Molecular deep profiling and integration of single cell data as a novel approach to stratify individuals undergoing integrated immuno-inflammatory treatment.
• Identification of cellular trajectories and interaction hubs of minimally-invasive pharmaceuticals.
The human immune system, when activated excessively and unlimitedly, can have pathological consequences. Extensive studies with innovative and rigorous methodologies have broadened our knowledge in this regard. Autoimmune and inflammatory diseases are split into two groups, but considering their similarities, can be considered as only one. Both autoimmune and inflammatory responses coexist, with the balance between the two being critical in shaping the clinical presentation of these diseases. Therapeutic cross-manipulations of these processes can be achieved by both the immunoregulatory and anti-inflammatory effects of various innovative compounds, including small-molecule drugs, vaccines and biologics. Immunopharmacology and inflammopharmacology are currently devoted to the discovery, development and implementation of preclinical and clinical molecules that can target the immune system or inflammation, respectively. What is even more highly anticipated, however, is the identification - at the level of individual cells - of molecular patterns and trajectories of pharmaceutical particles with bridged immunoregulatory and anti-inflammatory effects in the affected body, i.e. disturbed by conditions associated with immune-mediated inflammatory skin pathologies.
The goal of this Research Topic is to feature cutting-edge, high-resolution research describing the signature of pharmaceutical molecules in a single cell, related to the regulation of immune-inflammatory axis distortion of human diseases. Reports on strategies that could change the current standards for future patient management and reports on the assessment of efficacy, safety and quality of future health products are missing. Thus, perspectives on the most innovative immuno-inflammatory factors and pharmacological regulators are welcome. Experimental reports on and reviews of systemic and holistic approaches allowing clinicians to institute targeted and personalized medicine, leading to maximization of efficacy and minimization of toxicity, are sought. Such studies will allow us to overcome the biggest challenge we face in achieving more effective and safer, as well as long-term and stable remission in patients suffering from autoimmune inflammatory skin diseases. We believe that this Research Topic will show that expanding this area of research will be very valuable in better understanding of autoimmune inflammatory skin diseases and facilitate the progress of therapeutic procedures for them.
In this Research Topic, we are looking to publish studies that will fuel basic, translational and clinical research on immune-mediated inflammatory skin conditions. This collection should be a forum that allows communication between scientists, which will ultimately propel the translation of fundamental knowledge into early and improved pharmacological treatments for immune-mediated inflammatory skin conditions.
We welcome submissions of Original Research and Review articles addressing, but not limited to, the following aspects of pharmaceutical molecules with bridged immunoregulatory and anti-inflammatory action, in relation to autoimmune inflammatory skin diseases:
• Innovative therapy development strategies related to the identification of molecular patterns that better predict response to a given treatment; mechanisms of response and non-response to treatment using single-cell technologies and advanced bioinformatics.
• Molecular deep profiling and integration of single cell data as a novel approach to stratify individuals undergoing integrated immuno-inflammatory treatment.
• Identification of cellular trajectories and interaction hubs of minimally-invasive pharmaceuticals.
